Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FAIR-PARK II deferiprone trial in treatment-naive Parkinson's disease
NL-OMON47754Phase 2Active, not recruiting
- Sponsor
- CHU de Lille
- Start
- Oct 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Parkinson's disease (PD) comparing Ferriprox with Placebo (2 arms). Primary endpoints: Total MDS-UPDRS score at weeks 36 and 40, Combined disease progression criterion and 6 more. Started Oct 2016; status: active, not recruiting.
02
Drugs
deferiprone
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NL-OMON47754.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47754.